American Association for Cancer Research
15357163mct150892-sup-157259_3_supp_3447782_x5kx87.docx (13.69 kB)

Supplementary methods from The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide

Download (13.69 kB)
journal contribution
posted on 2023-04-03, 15:48 authored by Stefan Prekovic, Martin E. van Royen, Arnout R.D. Voet, Bart Geverts, Rene Houtman, Diana Melchers, Kam Y.J. Zhang, Thomas Van den Broeck, Elien Smeets, Lien Spans, Adriaan B. Houtsmuller, Steven Joniau, Frank Claessens, Christine Helsen

Protocol of the cell viability assay performed on LAPC4 cells.



KU Leuven




Treatment-induced mutations in the ligand-binding domain of the androgen receptor (AR) are known to change antagonists into agonists. Recently, the F877L mutation has been described to convert enzalutamide into an agonist. This mutation was seen to co-occur in the endogenous AR allele of LNCaP cells, next to the T878A mutation. Here, we studied the effects of enzalutamide on the F877L and T878A mutants, as well as the double-mutant AR (F877L/T878A). Molecular modeling revealed favorable structural changes in the double-mutant AR that lead to a decrease in steric clashes for enzalutamide. Ligand-binding assays confirmed that the F877L mutation leads to an increase in relative binding affinity for enzalutamide, but only the combination with the T878A mutation resulted in a strong agonistic activity. This correlated with changes in coregulator recruitment and chromatin interactions. Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR. Mol Cancer Ther; 15(7); 1702–12. ©2016 AACR.